Amsterdam, the Netherlands, July 31, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a recently-listed clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces the partial exercise of the Over-Allotment Option by Kempen & Co N.V. acting on behalf of the Underwriters and the end of the stabilisation period in relation to its initial public offering (the “IPO” or the “Offering”).
Kiadis Pharma had granted the Stabilisation Manager an option to purchase up to 392,045 additional shares at the Offer Price of EUR 12.50 to cover potential over-allotments or short positions in connection with the Offering, which option was exercisable for a period of 30 calendar days as from the first day of listing of the shares on Euronext Amsterdam and Euronext Brussels (i.e. 2 July 2015) (the “Over-Allotment Option”)
On 31 July 2015 the Stabilisation Manager exercised the Over-Allotment option for 163,500 shares, raising additional gross proceeds of € 2.0 million for Kiadis Pharma. As a result, the total number of shares sold by Kiadis Pharma in the IPO amounts to 2,777,136 shares, representing total gross proceeds of € 34.7 million from the Offering.
The stabilisation period commenced on 2 July 2015 and ended on 31 July 2015. Details of the stabilisation activity carried out by the Stabilisation Manager can be found in the table below. The new shares will be listed on Euronext Amsterdam and Euronext Brussels on or about 5 August 2015 and rank pari passu with the existing shares.
|Date||Price range of stabilisation trades|
|Lowest price||Highest price|
Kempen & Co N.V. is acting as Stabilisation Manager and Kempen & Co N.V., KBC Securities NV/SA and Peel Hunt LLP together act as Underwriters.
About Kiadis Pharma
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The Company believes that its innovative products have the potential to address the current risks and limitations connected with allogeneic hematopoietic stem cell transplantation (HSCT). Although currently not a viable option for many patients, HSCT is generally regarded as the most effective curative approach to blood cancers and certain inherited blood disorders. The Company expects that HSCT could become a first- choice treatment for blood cancers and inherited blood disorders once current risks and limitations are addressed, thereby meeting a significant unmet medical need with its products.
Currently, ATIRTM101 is being tested in an open-label Phase II trial in patients with blood cancer who have not found a matching donor and where a partially matched (haploidentical) family member is used as donor for HSCT.
Kiadis Pharma is based in Amsterdam, the Netherlands and its shares were admitted to listing and trading on Euronext Amsterdam and Euronext Brussels on 2 July 2015. Further information can be found at: www.kiadis.com/news/
This press release contains regulated information (gereglementeerde informatie) within the meaning of the Dutch Financial Supervision Act (Wet op het financieel toezicht) which must be made publicly available pursuant to Dutch law. This press release is intended for information purposes only.
Manfred Rüdiger, CEO
1114 AA Amsterdam-Duivendrecht The Netherlands
Tel. +31 20 314 02 50
International Media and Investor Contact:
Mary-Jane Elliott, Lindsey Neville, Hendrik Thys Consilium Strategic Communications
Tel: +44 (0) 203 709 5708 email@example.com
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma’s or, as appropriate, Kiadis Pharma’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward- looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Important Legal Information
This communication is not an offer to sell or a solicitation of any offer to buy the securities of Kiadis Pharma (the “Securities”) in the United States or in any other jurisdiction.
The Securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States unless registered under the Securities Act or an exemption from such registration is available. No public offering of Securities of the Company is being made in the United States.